Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children
- 1 November 2008
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 26 (50), 6383-6391
- https://doi.org/10.1016/j.vaccine.2008.08.046
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adultsVaccine, 2008
- Comparison of the Influenza Virus-Specific Effector and Memory B-Cell Responses to Immunization of Children and Adults with Live Attenuated or Inactivated Influenza Virus VaccinesJournal of Virology, 2007
- Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysisThe Lancet, 2006
- Prevention and Treatment of Influenza in High‐Risk Groups: Children, Pregnant Women, Immunocompromised Hosts, and Nursing Home ResidentsThe Journal of Infectious Diseases, 2006
- The Safety of Trivalent Influenza Vaccine Among Healthy Children 6 to 24 Months of AgePediatrics, 2006
- Mitigation strategies for pandemic influenza in the United StatesProceedings of the National Academy of Sciences, 2006
- Influenza related hospitalisations in Sydney, New South Wales, AustraliaArchives of Disease in Childhood, 2005
- Vaccination strategies for an influenza pandemic.The Journal of Infectious Diseases, 2005
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986